An Official Website of the United States Government
Company Information:
Name:
AUREOGEN BIOSCIENCES, INC.
Address:
6475 Technology Avenue, Ste C
KALAMAZOO, MI 49009-
KALAMAZOO, MI 49009-
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Novel Antifungals by Engineering the AbA NRPS gene
Award Year / Program / Phase:
2004 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Ake P. Elhammer
Award Amount:
$162,982.00
Abstract:
DESCRIPTION (provided by applicant): There is an immediate need for efficient, novel antifungal drugs. The fungus Aureobasidium pullulans produces a cyclic peptide know as Aureobasidin A (AbA) which is a very potent, fungicidal drug that is currently barred from commercialization due to a… More
Novel Antifungals by Engineering the AbA NRPS gene
Award Year / Program / Phase:
2006 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Ake P. Elhammer
Award Amount:
$1,978,701.00
Abstract:
DESCRIPTION (provided by applicant): There is an immediate need for novel drugs for the treatment of fungal infections, (antibiotics resistant) bacterial infections, and cancer. Cyclic peptides constitute a class of compounds that have made crucial contributions to the treatment of these diseases.… More
A Bacitracin derivative for systemic use
Award Year / Program / Phase:
2007 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Ake P. Elhammer
Award Amount:
$381,116.00
Abstract:
DESCRIPTION (provided by applicant): The number of patients treated for antibiotics-resistant infections has increased drastically in recent years. What started as a problem primarily associated with hospital-acquired Enterococcus infections, has not only
moved into the general community, but also… More
Generation of novel HCV drugs through engineereing of the cssA gene
Award Year / Program / Phase:
2008 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Ake P. Elhammer
Award Amount:
$600,000.00
Abstract:
DESCRIPTION (provided by applicant): HCV infections are a prevalent and growing health problem. It is estimated that as many as 2% of the US population, and 2.5% of the population world-wide, are infected by HCV. The disease currently causes 15,000 deaths/
year in US alone, a number that is… More
Generation of novel drugs against drug resistant bacteria through engineering of
Award Year / Program / Phase:
2008 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Ake P. Elhammer
Award Amount:
$286,746.00
Abstract:
DESCRIPTION (provided by applicant): The number of patients treated for antibiotics-resistant bacterial infections has increased drastically in recent years. What started as a problem primarily associated with hospital-acquired Enterococcus infections, has
not only moved into the general community,… More
Novel Antifungals by Engineering the AbA NRPS gene
Award Year / Program / Phase:
2011 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Ake P. Elhammer – 269-353-3805
Award Amount:
$481,481.00
Abstract:
DESCRIPTION (provided by applicant): The continuing increase in the number of surgery, transplantation, cancer and other immunocompromized patients, that need treatment for fungal infections, together with the fact that only one new class of antifungal therapeutics has been introduced to the market… More